DNAPrint Joins National Institutes of Justice Funded Project
Monday August 25,2003 -- 11:25 am ET
SARASOTA, Fla., Aug. 25 /PRNewswire-FirstCall/ -- DNAPrint Genomics, Inc. (OTC Bulletin Board: DNAP - News; DNAPrint or the "Company") announced today that it will serve as a subcontractor for a new National Institutes of Justice (the "NIJ") research grant.
DNAPrint will apply its expertise in the measurement of population structure and genome screening to assist the NIJ and the grantee map genetic markers of a certain forensics value, considered by the Company to be complementary to its DNAWitness efforts. The project is broken into two- phases, the first of which has already been approved. The Company would be paid approximately $50,000 to produce approximately 80,000 genotypes. Other details are not disclosed.
About DNAPrint genomics, Inc.
DNAPrint(TM) genomics, Inc., ("DNAPrint(TM)" or the "Company"), is a genomics science company focused on the sale of proprietary genetic testing products and services. The Company's core technologies for efficiently targeting single nucleotide polymorphisms ("SNPs") enable it to provide predictive genetic tests at a significant cost advantage over its competitors.
The Company has identified and patented the maps of certain SNPs with wide commercial applications. These commercially valuable SNP maps are called Ancestry Informative Markers ("AIMS"). The Company's patented AIMs are integral to the Company's strategy of offering DNA tests that provide valuable predictive results, including a person's physical characteristics, Biogeographical Ancestry ("BGA"), and predisposition to respond to certain pharmaceutical drugs. The Company's tests target four distinct markets -- forensics, consumer, and pharmacogenomics (predicting drug response) and outsourced screening services. The Company is traded on the Nasdaq OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit www.dnaprint.com.
All statements in this press release that are not historical are forward- looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
